Abstract
IL-17 is an important proinflammatory cytokine in autoimmune diseases. The constant presence of IL- 17 in the intestinal tract raises the possibility that it may be a critical enhancer of intestinal tumorigenesis. Yet the role of IL-17 in cancer development is controversial. Animal studies and clinical studies suggest that the role of IL-17 may be differential depending on type of cancer and tumor microenvironment. The role of IL- 17 in intestinal tumorigenesis is largely proinflammatory and likely affects Treg function. Thus, targeting IL- 17 in intestinal tumorigenesis may be an effective approach for treating cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | e79-e83 |
| Journal | Drug Discovery Today: Disease Mechanisms |
| Volume | 8 |
| Issue number | 3-4 |
| DOIs | |
| State | Published - 2011 |
| Externally published | Yes |
ASJC Scopus subject areas
- Molecular Medicine
- Drug Discovery